Investor Relations

Press Releases


NanoString Showcases Groundbreaking Body of Research at the 2018 Annual Meeting of the American Association for Cancer Research
More than 50 abstracts highlight the diverse capabilities of NanoString’s technology from gene expression profiling to Digital Spatial Profiling

SEATTLE, April 12, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced a record number of abstracts that will be presented at the American Association of Cancer Research (AACR) conference to be held April 14-18, 2018, in Chicago, Illinois.

“We’re proud of the extent to which our technologies are being showcased at AACR this year, and we are excited about the opportunities for growth as we extend our leadership in biomarker development and precision oncology,” said Brad Gray, president and CEO of NanoString.

More than 50 abstracts using NanoString’s technologies will be presented at AACR, including applications such as gene expression profiling in cancer and immuno-therapy using NanoString Panel products such as the PanCancer line and IO 360, high throughput cell line screening with PlexSet™ reagents and highly multiplexed protein quantification using Digital Spatial Profiling.

In addition, NanoString will be hosting a seminar entitled, “Powering Precision Oncology Research: Developing Gene Expression Signatures and High-Plex Digital Spatial Profiling,” on Monday April 16th from 10:00am–11:00am CT in Hall A of McCormick Place South.

Speakers will include:
David Rimm, MD, Ph.D., Yale University School of Medicine
Karen Leroy, MD, Ph.D., Universite Paris Descartes
Joseph Beechem Ph.D., NanoString Technologies

Below are a subset of abstracts that best illustrate the unique capabilities of NanoString’s technology platform. A complete list of 51 NanoString-enabled abstracts follows.

Digital Spatial Profiling
Title: Highly multiplexed analysis of immune cell subsets in non-small cell lung cancer: validation of protein and RNA analysis by the NanoString DSP platform
Date/Time: Monday, April 16 2018, 1pm-5:00pm CT
Author: James Zai, Genentech
Poster #/Location: 2089/Poster Section 4, Board 4
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/1925
Digital Spatial Profiling (DSP) shows high section to section reproducibility and correlation with flow cytometry and immunohistochemistry.

Title: Digital spatial profiling platform allows for spatially-resolved, high-plex quantification of mRNA distribution and abundance on FFPE and fresh frozen tissue sections
Date/Time: Tuesday, April 17 2018, 8am-12:00pm CT
Author: Daniel Zollinger, NanoString
Poster #/Location: 3434/Section 18, Board 16
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7119
Digital Spatial Profiling can be used to obtain high-plex, spatial mRNA expression data (10’s to 100’s of genes) and protein expression data on FFPE and fresh frozen tissue sections. 

Title: High-plex immune marker spatial profiling quantitation by NanoString® Digital Spatial Profiling technology and quantitative immunofluorescence
Date/Time: Tuesday, April 17, 2018, 8am-12:00pm CT
Author: Maria I. Toki, Yale University Medical Center
Poster #/Location: 3621/Section 25, Board 29
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/2962
Digital Spatial Profiling shows promise in a pilot study of 30 spatially resolved protein immune markers for prognostic significance in a EGFR TKI treated NSCLC cohort as well as an ITx treated Melanoma cohort, and high concordance with AQUA. A Quantitative Immunofluoresence Assay (AQUA™) is a method for quantifying proteins through immunofluorescence.

Title: Validation of Digital Spatial Profiling of Key Immuno-Oncology Targets for Mouse FFPE Preclinical Models
Date/Time: Tuesday, April 17, 8:00am-12:00pm CT
Author: Sarah Warren, Ph.D., NanoString
Poster #/Location: 3858/Section 36, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/3493
Digital Spatial Profiling allows for the multiplexing of 10s to 100s of proteins, and NanoString has validated an antibody panel designed to characterize key tumor and immunology markers for FFPE samples from mouse preclinical models.

PlexSet Abstracts
Title: Digital Gene Expression of up to 96 Targets in 96 Samples for Cell Line Screening with nCounter® PlexSet
Date/Time: Monday, April 16 2018, 1pm-5:00pm CT
Author: Giang T. Ong, NanoString
Poster #/Location: 2342/Section 16, Board 3
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7033
NanoString demonstrates that the nCounter Analysis System can detect gene expression in 96 genes for 96 samples in parallel from cell lysate using the lyse-and-go protocol and PlexSet panel. The data correlates well with purified total RNA and is an efficient solution for cell line screening studies.

Title: Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification
Date/Time: Tuesday, April 17 2018, 8:00am-12:00pm CT
Author: R. Venkatramanan et al, Covance
Poster #/Location: 3418/Section 16, Board 3
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7089
A comparison of PlexSet technology with various qPCR technologies on 96 colorectal FFPE samples. PlexSet, showed high correlation with RNA seq and robust reproducibility.

Gene Expression Profiling
Title: The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort
Date/Time: Tuesday, April 17, 2018, 1:00pm-5:00pm CT
Author: D. Damotte, et al, Univ. Paris Descartes APHP and INSERM
Poster #/Location: 4546/Section 25, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7648
The tumor inflammation signature (TIS) and other gene expression signatures, simultaneously analyzed using the IO 360 panel, predict clinical benefit of anti-PD1 treatment (nivolumab and pembrolizumab) in ‘real life’ patients with various cancer types, including NSCLC.

Title: Infiltrating immune cells in breast cancer subtypes
Date/Time: Tuesday, April 17 2018, 8:00am-12:00pm CT
Author: J.L. Matta et al, Ponce Health Sciences Institute and H. Lee Moffitt Cancer Center
Poster #/Location: 5698/Section 32, Board 4
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7977
Demonstrates the value of combining PAM50 subtype distribution with tumor immune profiling to identify biologically distinct patient populations; the combination of these signatures could be applied to the development of specific immunotherapeutics.

Title: The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab
Date/Time: Tuesday, April 17 2018, 1:00pm-5:00pm CT
Author: A. Waks et al, Dana Farber Cancer Institute
Poster #/Location: 4565/Section 26, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/7859
HR+/HER2- breast tumors with higher levels of tumor immune activity have a more favorable response to chemo plus bevacizumab. Deeper analysis into NanoString signatures show the underlying biological mechanisms of this observation: T-cell and checkpoint-related biomarkers decrease and chemokines and complement pathway genes increase following treatment.

Title: Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma
Date/Time: Sunday, April 15, 2018, 1:00pm-5:00pm
Author: M. Capone et al, A. Waks et al, Istituto Nazionale Tumori IRCCS Fondazione
Poster #/Location: 558/Section 25, Board 1
Hyperlink: http://www.abstractsonline.com/pp8/#!/4562/presentation/2941
The NanoString IO 360 Panel is used to characterize tumor and PMBC samples from patients with metastatic melanoma treated with either ipilimumab or pembrolizumab to characterize local and peripheral patterns of gene expression associated with clinical benefit of therapy.

Title: Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms
Date/Time: Tuesday, April 17, 2018, 1:00pm-5:00pm CT
Author: R. Novosiadly et al, Eli Lilly & Co
Poster #/Location: 4549/Section 25, Board 4
Pemetrexed promotes intra–tumor T cell–mediated immune response through immunogenic tumor cell death and increased activation and metabolic fitness of T cells, leading to an enhanced anti–tumor efficacy in combination with a PD–L1 antibody as shown by using NanoString for gene expression analysis of syngeneic tumor models.

Title: Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study
Date/Time: Monday, April 16, 2018, 1:00pm-5:00pm
Author: A. Naing, et al, MD Anderson and Neon Therapeutics
Poster #/Location: LB-147/Section 43, Board 14
Comprehensive immune profiling of two metastatic melanoma patients treated with a NEO-PC-01 in combination with nivolumab including deep immune profiling using NanoString’s Tumor Inflammation Signature and other IO signatures.
 

Abstract
#
Title Hyperlink
LB-147
Comprehensive immune and molecular analysis of two metastatic melanoma patients treated with a personal neoantigen vaccine, NEO-PV-01, in combination with anti-PD1: A case study
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/10469 
LB-394
Profiling of endogenous circular RNA molecules in formalin-fixed paraffin-embedded tissues from patients with B-cell malignancies using an enzyme-free digital counting method
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/10695
NG06
The clinico-genomics of localized, non-indolent prostate cancer: the CPC-GENE experience
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/10887
558
Prognostic gene signature use in checkpoint inhibitor monotherapy for melanoma
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2941
613
X4P-001, an orally bioavailable CXCR4 antagonist, enhances immune cell infiltration and activation in the tumor microenvironment of melanoma
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/8021
619
ALT-803 enhances antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NEO-201 against human carcinoma cells
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/8028
634
SOX11 is a potential clinical marker for hormone receptor negative ductal carcinoma in situ
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6349
982
Pharmacological DNA-PK inhibition induces ATM/p53 dependent premature senescence with immunomodulatory phenotype in irradiated cancer cells
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/9520
1020
Characterization of the immune landscape and analysis of tumor response after anti-PD-1 blockade in a 3D ex vivo system of non-small lung cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/1844
1038
Xenograft-associated B cell lymphoproliferative disease as a surrogate model to study Epstein-Barr virus (EBV) driven lymphoma of the elderly
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/4969
1053
Highly characterized patient-derived PDX breast cancer collection for preclinical efficacy studies
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/4984
1361
Micro RNA-200C is one of the important Fanconi Anemia (FA) pathway downstream regulators in lung cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6297
1548
Genetic biomarkers predict clinical response and survival in myelodysplasia
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2737
1584
Comparison of circulating tumor cell (CTC) capture/identification methods and NanoString evaluation of gene expression in CTCs and cell-free circulating tumor mRNA (cctmRNA) in patients with metastatic lung cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2667
1609
Simple and rapid high-plex analysis of RNA and protein from low-frequency sorted T cells
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6417
1684
Selective SIRPa blockade potentiates dendritic cell antigen cross-presentation and triggers memory T-cell antitumor responses
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7704
1767
Synergy between intratumoral immunotoxin and systemic anti-CTLA-4 promotes massive inflammation and leads to complete regression of tumors in mice
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/8453
1981
Pan-cancer pathways gene expression profiling in mantle cell lymphoma reveals upregulation of DNA damage repair genes in ibrutinib-resistant tumor
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/5717
1985
Upregulation of miR-328 contributes to ovarian cancer stem cell maintenance by downregulating DDB2
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6165
2081
Empowering rare disease cohort biomarker discovery via comparative assessments of gene expression analysis platforms for FFPE pediatric brain tumor specimens
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/4193
2089
Highly multiplexed analysis of immune cell subsets in non-small cell lung cancer: validation of protein and RNA analysis by the Nanostring Digital Spatial Profiling (DSP) platform
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/1925
2342
Digital gene expression of up to 96 targets in 96 samples for cell line screening with nCounter® PlexSet™
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7033
2555
Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in solid tumors
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7454
2982
Somatic TP53 mutations alter the immune microenvironment after chemotherapy in breast cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/4162
3141
Immune gene expression and prognosis in localized clear cell (cc) renal cell carcinoma (RCC)
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/1618
3145
Characterization of novel immune checkpoint receptors within the breast cancer tumor microenvironment
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/1622
3397
Clinical significance of 3q amplification in squamous cell carcinoma of lung
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7067
3418
Cross-Comparison of Targeted Gene Expression Technologies for Patient Stratification
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7089
3425
Exome-sequencing derived mutations of endocrine treated ER-positive early breast cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7110
3434
Digital spatial profiling platform allows for spatially resolved, high-plex quantification of mRNA distribution and abundance on FFPE and fresh frozen tissue sections
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7119
3497
Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/8884
3593
Noncoding RNAs in early detection of radiation-induced late pulmonary effects
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2860
3607
Quantitative dimensions of the PAM50 in breast tumors are prognostic and predict paclitaxel response
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2899
3621
High-plex immune marker spatial profiling quantitation by NanoString Digital Spatial Profiling technology and quantitative immunofluorescence
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2962
3682
Expression levels of genes in primary melanoma associated with clinically meaningful characteristics
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6389
3692
PRECISION (Profiling Early Breast Cancer for radiotherapy Omission): An ongoing phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6399
3700
A window into human tumor progenitor cell subsets: Functionalizing a novel platform, the micropallet array, for molecular evaluation of single adherent cells with defined cell surface phenotype
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6377
3858
Validation of digital spatial profiling of key immuno-oncology targets for mouse FFPE preclinical models
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/3493
3937
Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/6762
3998
Integrative molecular analysis uncovers key molecules and signaling pathways regulated by RKIP in gastrointestinal stromal tumors (GISTs)
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/4543
4213
Molecular biomarker study of programmed death receptor ligand 1 (PD-L1) in Korean patients with lung adenocarcinoma
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/5416
4217
Prognostic gene expression signatures of immune responses in the colon cancer microenvironment
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/5420
4437
Down-modulation of ADAR1-mediated GLI1 editing alters extracellular and immune response genes in multiple myeloma
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2269
4525
Cancer/testis antigens: A biomarker panel for prostate cancer screening
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/2736
4546
The tumor inflammation signature is predictive of anti-PD1 treatment benefit in the CERTIM pan-cancer cohort
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7648
4549
Pemetrexed enhances anti-tumor efficacy of PD1 pathway blockade by promoting intra tumor immune response via immunogenic tumor cell death and T cell intrinsic mechanisms
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7651
4564
The immune microenvironment in hormone receptor-positive breast cancer and treatment outcome following preoperative chemotherapy plus bevacizumab
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7859
4707
Pelareorep promotes the expression of a chemokine signature that predicts response to immunotherapy
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/8181
4965
Entinostat transforms the suppressive tumor microenvironment of breast cancer and promotes survival and anti-responses when combined with checkpoint inhibition
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/3695
5402
A panel of miRNAs for diagnosis of wild-type thyroid nodules with pre-surgical indeterminate cytology
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/5923
5698
Infiltrating immune cells in breast cancer
 
http://www.abstractsonline.com/pp8/#!/4562/presentation/7977

About NanoString Technologies, Inc.

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in more than 1,900 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology is also being used in diagnostics. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer. In addition, the company collaborates with biopharmaceutical companies in the development of companion diagnostic tests for various cancer therapies, helping to realize the promise of precision oncology.

For more information, please visit www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions. AQUA™ is a trademark of Genoptix. All third party trademarks are the property of their respective owners.

Contact:

Doug Farrell
Vice President, Investor Relations & Corporate Communications
dfarrell@nanostring.com
Phone: 206-602-1768

 

Primary Logo

 

Source: NanoString Technologies, Inc.